Paroxetine

• 

  Subject Areas on Research

  • A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. 
  • A pilot randomized controlled trial with paroxetine for subthreshold PTSD in Operation Enduring Freedom/Operation Iraqi Freedom era veterans. 
  • A randomized controlled trial of paroxetine for noncardiac chest pain. 
  • A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. 
  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
  • Advances in Pharmacotherapy of Late-Life Depression. 
  • Alterations in serotonin transporter expression in brain regions of rats exposed neonatally to chlorpyrifos. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. 
  • Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. 
  • Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. 
  • Correlates of remission in primary care patients treated for minor depression. 
  • Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal model. 
  • Effects of paroxetine and venlafaxine XR on heart rate variability in depression. 
  • Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. 
  • Exposure to SSRI-type antidepressants increases righting time in the marine snail Ilyanassa obsoleta. 
  • Fetal and adolescent nicotine administration: effects on CNS serotonergic systems. 
  • Further studies on platelet serotonin transporter binding in depression. 
  • History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. 
  • History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. 
  • Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. 
  • Isn't It About Time to Employ Measurement-Based Care in Practice? 
  • Management of posttraumatic stress disorder: diagnostic and therapeutic issues. 
  • Modeling geriatric depression in animals: biochemical and behavioral effects of olfactory bulbectomy in young versus aged rats. 
  • Motor cortex excitability after vagus nerve stimulation in major depression. 
  • Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. 
  • Paroxetine as a treatment for premenstrual dysphoric disorder. 
  • Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. 
  • Paroxetine in the treatment of generalised anxiety disorder. 
  • Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. 
  • Paroxetine-pimozide drug interaction. 
  • Paroxetine: safety and tolerability issues. 
  • Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. 
  • Pharmacologic treatment of acute and chronic stress following trauma: 2006. 
  • Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. 
  • Pharmacotherapy of social anxiety disorder: what does the evidence tell us? 
  • Predictors of nonresponse to treatment in primary care patients with dysthymia. 
  • Programming of brainstem serotonin transporter development by prenatal glucocorticoids. 
  • Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. 
  • Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. 
  • Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. 
  • Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. 
  • Selective serotonin reuptake inhibitors for fibromyalgia syndrome. 
  • Serotonin syndrome after a massive overdose of controlled-release paroxetine. 
  • Serotonin transporter expression in rat brain regions and blood platelets: aging and glucocorticoid effects. 
  • Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. 
  • Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy. 
  • St John's for depression, worts and all. 
  • Status of minor depression or dysthymia in primary care following a randomized controlled treatment. 
  • The long-term treatment of panic disorder. 
  • The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. 
  • The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. 
  • Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. 
  • Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. 
  • Treatment of mild depression in elderly patients. 
  • Treatment of posttraumatic stress disorder: the impact of paroxetine. 
  • When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology